Inflammation: Hallmark and Driver of Numerous Diseases

The drug discovery targets in Elgia’s platform are linked to chronic inflammatory disease states and the company holds proprietary intellectual property from the founders’ pioneering research in innate immunity, metabolic stress, inflammatory processes, and medicinal chemistry. Inhibitors for genes encoding proteins in the caspase and kinase families known to be elevated in many chronic inflammatory and fibrotic diseases are progressing through our pipeline.

Short Term Wins and Future Expansion

The Elgia product pipeline is staged to initially establish the efficacy of novel inhibitors in clinical trials focused on chronic inflammatory diseases such as liver fibrosis, kidney disease, lupus, cryopyrin-associated periodic syndrome (CAPS) or inflammatory bowel disease (IBD). Expanded indications, such as NASH, neuroinflammation and cancer will then be explored.

Targets Integral to Inflammation Resolution and Reduction of Fibrosis